Search results for " Side Effects"
showing 3 items of 123 documents
Management of Statin Intolerance in 2018: Still More Questions Than Answers.
2018
Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…
Diabēta medikamentu blakusparādības
2016
Ievads: Vēljoprojām ir sastopamas nozīmīgas blaknes diabēta zālēm, kas ir īpaši nozīmīgi pieaugot saslimstībai ar diabētu pasualē, kā arī Latvijā. Atpazīt diabēta medikamentu izraisītās blaknes ir svarīgi, lai novērstu smagās komplikācijas, ko tās var radīt. Pētijuma mērķis: pētījuma mērķis bija konstatēt blakņu esamību hospitalizētajiem diabēta pacientiem. Materiāli un Metodes: pētījumi, iekļāva pacientus, kuri diagnozticēti ar diabetes mellitus. Pacienti tika iztaujāti par medikamentiem, kurus viņi lieto atveseļošanās periodā un par viņu zināmām vai nezināmajām novērotajām blaknēm. Rezultāti: Pētījumā tika iekļauti 50 pacienti, ar abu, 1. un 2. tipa diabētiem. Pētāmo pacientu grupa sastāv…
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
2019
The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogressio…